Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + irinotecan for metastatic or recurrent malignant melanoma
KCT0012582Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and irinotecan in melanoma, sponsored by Boryung. Primary endpoint: objective response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pembrolizumabirinotecan
03
Conditions
melanoma
Beyond the preview
Go deeper on KCT0012582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012582.